Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07491328 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Liquid Biopsy in Paraneoplastic Neurological Syndromes

Study acronym: LiB-PNS
StatusRecruiting
PhaseNot specified
Started2023-05-20
View on ClinicalTrials.gov ↗
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
Trial Details
NCT Number NCT07491328
Lead Sponsor Heinrich-Heine University, Duesseldorf
Collaborators: University of Regensburg, Universität Münster, Erasmus Medical Center, Medical University of Graz
Conditions Paraneoplastic Neurological Syndromes
Enrollment 60 participants
Start Date 2023-05-20
Primary Completion 2030-12-30 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-24